Updates are available Correction dated 2025-09-15
Click to view Correction: https://doi.org/10.1038/s41380-025-03121-x
-
Authors
Feng, Xiao
Jia, Min
Cai, Meng
Zhu, Tong
Hashimoto, Kenji https://orcid.org/0000-0002-8892-0439
Yang, Jian-Jun
- License Information
-
More Information
Article History
Received: 25 October 2024
Revised: 20 May 2025
Accepted: 11 June 2025
First Online: 3 July 2025
Change Date: 17 July 2025
Change Type: Update
Change Details: The original online version of this article was revised: In this article, the order in which the authors appeared in the author list was incorrectly given as Xiao Feng, Min Jia, Meng Cai, Tong Zhu, Jian-Jun Yang and Kenji Hashimoto where it should have been Xiao Feng, Min Jia, Meng Cai, Tong Zhu, Kenji Hashimoto & Jian-Jun Yang. The original article has been corrected.
Change Date: 15 September 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41380-025-03121-x
Competing interests
: Dr. Hashimoto is one of the editorial board members of this journal. Dr. Hashimoto is the inventor of filed patent applications on “The use of R-ketamine in the treatment of psychiatric diseases”, “(S)-norketamine and salt thereof as pharmaceutical”, “R-ketamine and derivative thereof as prophylactic or therapeutic agents for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, “R-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder”, and “TGF-β1 in the treatment of depression” by the Chiba University. Dr. Hashimoto also declares that he has received research support and consultant from Otsuka. Other authors have no conflict of interest.
